Onconova Therapeutics Inc (ONTX)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Steven M. Fruchtman
Employees:
20
375 PHEASANT RUN, NEWTOWN, PA, 18940
267-759-3681
Date | Ratio |
---|---|
2016-06-01 | 1:10 |
2018-09-26 | 1:15 |
2021-05-21 | 1:15 |
Onconova Therapeutics, Inc. focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|